Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces

References

• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 Apr 29:202005615. [Epub ahead of print]. doi:10.1073/pnas.2005615117.
   Web of Science ®Google Scholar
• Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020 May 3:102568. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2:247–256.
   PubMedGoogle Scholar
• Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm. 2008;65:1413–1418.
   PubMed Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–248.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA Approval Summary: tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23:943–947.
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Crotti C, Becciolini A, et al. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2018;13:57–70.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–1660.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377:317–328.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44:717–723.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57:856–864.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69:668–675.
   PubMed Web of Science ®Google Scholar
• Soriano A, Soriano M, Espinosa G, et al. Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome: evidence-based approach and proposal of a practical guide. Front Immunol. 2020;11:865.
   PubMed Web of Science ®Google Scholar
• Castañeda S, Martínez-Quintanilla D, Martín-Varillas JL, et al. Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opin Biol Ther. 2019;19:273–286.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659–1665.
   PubMed Web of Science ®Google Scholar
• Mehta P, Cron RQ, Hartwell J, et al. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020 May 4. [Epub ahead of print].
   PubMedGoogle Scholar
• Hernández-Rodríguez J, Ruiz-Ortiz E, Yagüe J. Monogenic autoinflammatory diseases: general concepts and presentation in adult patients. Med Clin (Barc). 2018;150:67–74.
   PubMed Web of Science ®Google Scholar
• Watanabe E, Sugawara H, Yamashita T, et al. Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still’s Disease: A Case-Based Review. Case Rep Med. 2016;2016:5656320.
   PubMed Web of Science ®Google Scholar
• Lenert A, Oh G, Ombrello MJ, et al. Clinical characteristics and comorbidities in adult-onset Still’s disease using a large US administrative claims database. Rheumatology (Oxford). 2020 Jan 21:pii: kez622. [Epub ahead of print].
   Web of Science ®Google Scholar
• Gavand PE, Serio I, Arnaud L, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmun Rev. 2017;16:743–749.
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 May 7. [Epub ahead of print].
   PubMedGoogle Scholar
• González-García A, García-Sánchez I, Lopes V, et al. Successful treatment of severe COVID-19 with anakinra as a sole treatment. Rheumatology (Oxford). 2020. [in press].
   PubMedGoogle Scholar
• Ahmadpoor P, Rostaing L. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. Transpl Int. 2020 Apr 1. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 May 7. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Cheng CY, Lee YL, Chen CP, et al. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020;S1684–1182(20)30092–X.
   Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: remdesivir is helpful but not a wonder drug, say researchers. BMJ. 2020 May;1(369):m1798.
   Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;e200994. [Epub ahead of print].
   Web of Science ®Google Scholar